Explanation for the decline in coronary heart disease mortality rates in Auckland, New Zealand, between 1982 and 1993

Circulation

Volumn 102, Issue 13, 2000, Pages 1511-1516

  Capewell, Simon ^a   Beaglehole, Robert ^b   Seddon, Mary ^c   McMurray, John ^c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c WESTERN INFIRMARY   (United Kingdom)

Author keywords

Coronary disease; Drugs; Mortality; Population; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SIMVASTATIN; WARFARIN;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MORTALITY; NEW ZEALAND; PRIORITY JOURNAL; RISK FACTOR; SECONDARY PREVENTION; SMOKING;

EID: 0034718443     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.13.1511     Document Type: Article

References (41)

1. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study
2. Estimation of contribution of changes in classic risk factors to trends in coronary event rates across the WHO MONICA Project populations
3. Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland
4. Decline in ischaemic heart disease in Iceland and change in risk factor levels
5. Trends in coronary heart disease mortality and morbidity in Auckland, New Zealand, 1974-86
6. Evidence-based medicine and treatment choices
7. Recent trends in acute coronary heart disease: Mortality, morbidity, medical care, and risk factors
8. Contribution of modern cardiovascular treatment to the decline in coronary heart disease mortality in Scotland between 1975 and 1995
9. Medical management and the decline in mortality from coronary heart disease
10. Management of acute myocardial infarction in Auckland
11. Hospital admissions and deaths due to congestive heart failure in New Zealand, 1988-91
12. Trends and determinants of blood pressure in Auckland, New Zealand 1982-94
13. Collaborative overview of randomised trials of antiplatelet therapy, 1: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
14. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
15. Benefit of heparin plus aspirin versus aspirin alone in unstable angina
16. Blood pressure, stroke and coronary heart disease, part 2: Short term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context
17. Overview of randomized trails of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
18. Cumulative meta-analysis of therapeutic trials for myocardial infarction
19. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
20. Meta analysis of randomized trials comparing coronary angioplasty with bypass-surgery
21. Effect of coronary artery bypass graft surgery on survival: Overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists' Collaboration
22. Detecting differences in quality of care: The sensitivity of measures of process and outcome in treating acute myocardial infarction
23. A critical evaluation of the methodology of the literature on medication compliance
24. Trends in coronary heart disease risk factors in Auckland 1982-94
25. Relations of charges in coronary disease rates and changes in risk factor levels: Methodological issues and a practical example
26. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?
27. Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley survey: Comparison with men
28. Uncertainty in the economic evaluation of health care technologies: The role of sensitivity analysis
29. The impact of high risk patients on the population risk and on the population treatment effect
30. Increasing the impact of cardiological treatments: How best to reduce deaths
31. The decline in ischemic heart disease morality rates: An analysis of the comparative effects of medical interventions and changes in lifestyle
32. Decline of coronary heart disease mortality in the Netherlands 1978-1985: Contribution of medical care and changes over time in presence of major cardiovascular risk factors
33. The recent decline in mortality from coronary heart disease, 1980-1990: The effect of secular trends in risk factors and treament